Orphan Drug Status Goes to Engineered T-Cell Product

The U.S. Food & Drug Administration has awarded Orphan Drug Status to Kite Pharma for the company's engineered T-cell product.

Kite Pharma's engineered T-cell product is designed to treat difficult-to-treat cases of diffuse large B-cell lymphoma. This is an autologous T-cell, meaning it is contributed by the patient and then engineered in a laboratory before being returned to the patient.

Company aims for 'Holy Grail' of cancer treatment

In this case, Kite Pharma's engineering teaches the T-cells to target CD19 protein expression on the surface of B-cell lymphocytes and to kill them, effectively enlisting the body's own immune system to fight cancer – a goal considered by many to be the Holy Grail of cancer treatment.

Kite Pharma was launched five years ago, in 2009. They have been part of a cooperative research and development agreement with the National Cancer Institute's surgery branch to develop this Chimeric Antigen Receptor CD19 technology.

A pair of studies presented at the ASH conference in December showed the potential efficacy of the treatment in a handful of DLBCL patients.

Source: Healio

More Articles

More Articles

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Lymphoma is a life-threatening disease, but is very treatable in most cases. The 5-year survival for patients diagnosed with non-Hodgkin's...

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...